Analysis of Nuclear Receptor Coactivator 5 (NCOA5) Messenger RNA Expression and rs2903908 Single Nucleotide Polymorphism of NCOA5 in an Egyptian Cohort with Behçet's Disease : A Single-Center Case-control Study
The nuclear receptor coactivator 5 (NCOA5) has been linked to several inflammatory disorders, including Behçet's disease (BD). We evaluated the expression of NCOA5 messenger RNA (mRNA) using real-time reverse transcription-polymerase chain reaction, and analyzed the rs2903908 T > C of NCOA5 using TaqMan allelic discrimination assay in 49 Egyptian BD patients and 50 controls. The NCOA5 mRNA levels were higher in patients compared to controls (p = .02), female patients compared to males (p = .037), and in patients with ocular involvement (p = .049). Non-CC genotype carriers had a higher frequency of articular manifestations compared with CC carriers (p = .047). Genotypes CC + CT were associated with reduced risk of cutaneous involvement (OR = 0.27, p = .04). CC carriers with active BD or cutaneous manifestations displayed significantly lower NCOA5 mRNA expression than TT carriers. Our results demonstrate that NCOA5 is linked to BD clinical findings and activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Ocular immunology and inflammation - 30(2022), 6 vom: 19. Aug., Seite 1436-1446 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koptan, Dina M T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 21.11.2022 Date Revised 21.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/09273948.2021.1889610 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328012785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328012785 | ||
| 003 | DE-627 | ||
| 005 | 20231225202041.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/09273948.2021.1889610 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM328012785 | ||
| 035 | |a (NLM)34255592 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koptan, Dina M T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of Nuclear Receptor Coactivator 5 (NCOA5) Messenger RNA Expression and rs2903908 Single Nucleotide Polymorphism of NCOA5 in an Egyptian Cohort with Behçet's Disease |b A Single-Center Case-control Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2022 | ||
| 500 | |a Date Revised 21.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The nuclear receptor coactivator 5 (NCOA5) has been linked to several inflammatory disorders, including Behçet's disease (BD). We evaluated the expression of NCOA5 messenger RNA (mRNA) using real-time reverse transcription-polymerase chain reaction, and analyzed the rs2903908 T > C of NCOA5 using TaqMan allelic discrimination assay in 49 Egyptian BD patients and 50 controls. The NCOA5 mRNA levels were higher in patients compared to controls (p = .02), female patients compared to males (p = .037), and in patients with ocular involvement (p = .049). Non-CC genotype carriers had a higher frequency of articular manifestations compared with CC carriers (p = .047). Genotypes CC + CT were associated with reduced risk of cutaneous involvement (OR = 0.27, p = .04). CC carriers with active BD or cutaneous manifestations displayed significantly lower NCOA5 mRNA expression than TT carriers. Our results demonstrate that NCOA5 is linked to BD clinical findings and activity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NCOA5 | |
| 650 | 4 | |a Ocular Behçet’s disease | |
| 650 | 4 | |a mRNA | |
| 650 | 4 | |a real-time polymerase chain reaction | |
| 650 | 4 | |a rs2903908 | |
| 650 | 7 | |a Nuclear Receptor Coactivators |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a NCOA5 protein, human |2 NLM | |
| 700 | 1 | |a Rasheed Bahgat, Dina M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrasool, Asmaa A |e verfasserin |4 aut | |
| 700 | 1 | |a Allam, Riham S H M |e verfasserin |4 aut | |
| 700 | 1 | |a Elgengehy, Fatema T |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel Baki, Noha M |e verfasserin |4 aut | |
| 700 | 1 | |a Medhat, Basma M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ocular immunology and inflammation |d 1993 |g 30(2022), 6 vom: 19. Aug., Seite 1436-1446 |w (DE-627)NLM091014069 |x 1744-5078 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2022 |g number:6 |g day:19 |g month:08 |g pages:1436-1446 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/09273948.2021.1889610 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2022 |e 6 |b 19 |c 08 |h 1436-1446 | ||